Clinical Trial Update: MICI-CMV:Valganciclovir in Recurrent Bouts of Cryptogenic Inflammatory Bowel Diseases With an Infection by Cytomegalovirus [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating valganciclovir for recurrent cytomegalovirus-associated inflammatory bowel disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infections
• Inflammatory Bowel Diseases

Drugs mentioned

• Valcyte (valganciclovir)

Snippet

Sponsor: University Hospital, Grenoble | Conditions: Cytomegalovirus Infections, Inflammatory Bowel Diseases | Phase 3 | Status: TERMINATED